Last Updated:
10 Mar 2026, 03:30:00 PM (IST)
Dr. Reddy's Laboratories Limited
NSE: DRREDDY BSE: DRREDDY
NSE
1,314.60
27.60 (2.14%)
Prev Close
1287
Open Price
1288
Volume
2,328,593
Today Low / High
1288 / 1329.6
52 WK Low / High
1020 / 1379.7
Range
1,249 - 1,380
BSE
1,313.90
27.50 (2.14%)
Prev Close
1286.4
Open Price
1281.9
Volume
39,528
Today Low / High
1281.9 / 1329
52 WK Low / High
1025.9 / 1377.95
Range
1,248 - 1,380
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1314.6 (target range: 1,249 - 1,380), reflecting a change of 27.6 (2.14452%). On the BSE, it is listed at 1313.9 (target range: 1,248 - 1,380), showing a change of 27.5 (2.13775%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Dr. Reddy's Laboratories Limited Graph
Dr. Reddy's Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dr. Reddy's Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,314.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,313.90 | 1,327.04 | 1,194.34 - 1,459.74 |
| 1,340.18 | 1,072.14 - 1,608.21 | ||
| 1,353.32 | 947.32 - 1,759.31 | ||
| Bearish Scenario | 1,313.90 | 1,300.76 | 1,170.68 - 1,430.84 |
| 1,287.62 | 1,030.10 - 1,545.15 | ||
| 1,274.48 | 892.14 - 1,656.83 |
Overview of Dr. Reddy's Laboratories Limited
ISIN
INE089A01031
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,560,919
Market Cap
1,077,692,658,712
Last Dividend
8
Official Website
IPO Date
1996-01-01
DCF Diff
-1,877.71
DCF
3,172
Financial Ratios Every Investor Needs
Stock Dividend of DRREDDY
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-10 | July 10, 25 | 8 | 8 | 2025-07-10 | 2025-08-23 | |
| 2024-07-16 | July 16, 24 | 691.056 | 3455.28 | 2024-07-16 | 2024-08-28 | |
| 2023-07-11 | July 11, 23 | 8 | 40 | 2023-07-11 | 2023-08-26 | |
| 2022-07-11 | July 11, 22 | 6 | 30 | 2022-07-12 | 2022-08-28 | |
| 2021-07-09 | July 09, 21 | 5 | 25 | 2021-07-12 | 2021-08-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32,553.50 Cr | 13,510.70 Cr | 19,042.80 Cr | 0.5850 | 2,738.00 Cr | 0.00 Cr | 7,184.30 Cr | 5,654.40 Cr | 67.88 | 8,884.00 Cr | 0.1737 |
| 2024-03-31 | 27,916.40 Cr | 11,555.70 Cr | 16,360.70 Cr | 0.5861 | 2,287.30 Cr | 0.00 Cr | 6,772.90 Cr | 5,568.40 Cr | 66.93 | 7,928.60 Cr | 0.1995 |
| 2023-03-31 | 24,587.90 Cr | 10,653.60 Cr | 13,934.30 Cr | 0.5667 | 1,938.10 Cr | 0.00 Cr | 5,714.40 Cr | 4,506.70 Cr | 54.29 | 6,605.20 Cr | 0.1833 |
| 2022-03-31 | 21,439.10 Cr | 10,055.10 Cr | 11,384.00 Cr | 0.5310 | 1,748.20 Cr | 0.00 Cr | 2,947.60 Cr | 2,356.80 Cr | 28.42 | 4,774.30 Cr | 0.1099 |
| 2021-03-31 | 18,972.20 Cr | 8,664.50 Cr | 10,307.70 Cr | 0.5433 | 1,654.10 Cr | 0.00 Cr | 2,428.00 Cr | 1,723.80 Cr | 20.79 | 4,570.60 Cr | 0.0909 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,465.40 Cr | 49,298.90 Cr | 15,582.30 Cr | 33,338.8000 Cr | 4,676.60 Cr | 3,211.20 Cr | 7,108.50 Cr | 9,776.10 Cr | 0.00 Cr | 116.20 Cr | 1,520.20 Cr | 13,039.2000 Cr |
| 2024-03-31 | 710.70 Cr | 38,751.80 Cr | 10,696.80 Cr | 28,055.0000 Cr | 2,002.00 Cr | 1,291.30 Cr | 6,355.20 Cr | 7,688.60 Cr | 143.50 Cr | 119.30 Cr | 525.50 Cr | 9,603.9000 Cr |
| 2023-03-31 | 577.90 Cr | 32,285.10 Cr | 8,999.00 Cr | 23,099.1000 Cr | 1,347.20 Cr | 769.30 Cr | 4,867.00 Cr | 5,654.20 Cr | 198.10 Cr | 155.50 Cr | 536.20 Cr | 8,572.1000 Cr |
| 2022-03-31 | 1,485.20 Cr | 29,665.40 Cr | 10,612.70 Cr | 19,052.7000 Cr | 3,384.50 Cr | 1,899.30 Cr | 5,088.40 Cr | 6,216.90 Cr | 257.60 Cr | 159.70 Cr | 798.60 Cr | 9,401.5000 Cr |
| 2021-03-31 | 1,482.90 Cr | 26,549.10 Cr | 9,051.00 Cr | 17,306.2000 Cr | 3,030.80 Cr | 1,547.90 Cr | 4,541.20 Cr | 5,711.10 Cr | 203.30 Cr | 153.10 Cr | 833.30 Cr | 8,339.1000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,642.8000 Cr | -5,102.1000 Cr | 1,185.5000 Cr | 1,892.4000 Cr | 748.6000 Cr | 1,459.3000 Cr | -2,750.4000 Cr | 5,654.4000 Cr | -129.4000 Cr | -666.2000 Cr | -1,275.3000 Cr |
| 2024-03-31 | 4,543.3000 Cr | -4,028.3000 Cr | -376.3000 Cr | 1,799.8000 Cr | 132.8000 Cr | 710.7000 Cr | -2,743.5000 Cr | 5,568.4000 Cr | 434.6000 Cr | -664.8000 Cr | -1,844.5000 Cr |
| 2023-03-31 | 5,887.3000 Cr | -4,137.1000 Cr | -2,686.1000 Cr | 4,000.9000 Cr | -907.3000 Cr | 577.9000 Cr | -1,886.4000 Cr | 6,048.5000 Cr | -2,039.7000 Cr | -497.9000 Cr | -265.4000 Cr |
| 2022-03-31 | 2,810.8000 Cr | -2,638.7000 Cr | -242.2000 Cr | 905.9000 Cr | 3.2000 Cr | 1,485.2000 Cr | -1,904.9000 Cr | 2,356.8000 Cr | 273.5000 Cr | -414.6000 Cr | -532.8000 Cr |
| 2021-03-31 | 3,570.3000 Cr | -2,266.0000 Cr | -29.8000 Cr | 2,314.2000 Cr | 1,285.8000 Cr | 1,482.0000 Cr | -1,256.1000 Cr | 1,914.9000 Cr | 609.4000 Cr | -414.7000 Cr | -988.1000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 8,726.80 Cr | 4,046.20 Cr | 4,680.60 Cr | 0.5363 | 1,423.80 Cr | 1,209.80 Cr | 14.53 | 2,158.60 Cr | 0.1386 |
| 2025-09-30 | 8,805.10 Cr | 3,991.10 Cr | 4,814.00 Cr | 0.5467 | 1,751.30 Cr | 1,437.20 Cr | 17.22 | 2,430.80 Cr | 0.1632 |
| 2025-06-30 | 8,545.20 Cr | 3,682.50 Cr | 4,862.70 Cr | 0.5691 | 1,747.50 Cr | 1,417.80 Cr | 17.04 | 2,228.00 Cr | 0.1659 |
| 2025-03-31 | 8,506.00 Cr | 3,779.70 Cr | 4,726.30 Cr | 0.5556 | 1,764.70 Cr | 1,593.80 Cr | 19.13 | 2,065.30 Cr | 0.1874 |
| 2024-12-31 | 8,358.60 Cr | 3,453.40 Cr | 4,905.20 Cr | 0.5868 | 1,872.00 Cr | 1,413.30 Cr | 16.96 | 2,342.70 Cr | 0.1691 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,865.70 Cr | 6,393.20 Cr | 8,258.90 Cr | 12,426.90 Cr | 7,900.90 Cr | 29,754.90 Cr | 11,554.40 Cr | 56,289.90 Cr | 18,714.30 Cr |
| 2025-09-30 | 990.60 Cr | 5,990.50 Cr | 6,981.10 Cr | 12,084.10 Cr | 7,582.10 Cr | 27,951.70 Cr | 11,198.10 Cr | 54,200.50 Cr | 17,992.30 Cr |
| 2025-06-30 | 900.40 Cr | 5,768.40 Cr | 6,668.80 Cr | 11,544.30 Cr | 7,560.00 Cr | 26,989.80 Cr | 10,278.40 Cr | 51,953.70 Cr | 16,578.20 Cr |
| 2025-03-31 | 1,465.40 Cr | 4,325.40 Cr | 5,790.80 Cr | 9,042.00 Cr | 7,108.50 Cr | 25,011.20 Cr | 9,776.10 Cr | 49,298.90 Cr | 15,582.30 Cr |
| 2024-12-31 | 1,228.90 Cr | 4,689.00 Cr | 5,917.90 Cr | 11,149.40 Cr | 7,163.00 Cr | 25,301.60 Cr | 9,305.30 Cr | 48,105.90 Cr | 15,949.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,189.70 Cr | 1,033.10 Cr | -1,065.10 Cr | 871.30 Cr | 875.10 Cr | 1,865.70 Cr | 990.60 Cr | -670.40 Cr | 362.70 Cr |
| 2025-09-30 | 1,426.80 Cr | 1,557.30 Cr | -954.30 Cr | -532.30 Cr | 90.20 Cr | 990.60 Cr | 900.40 Cr | -1,013.50 Cr | 543.80 Cr |
| 2025-06-30 | 1,409.60 Cr | 1,462.90 Cr | -1,919.20 Cr | -120.30 Cr | -558.90 Cr | 900.40 Cr | 1,459.30 Cr | -1,014.70 Cr | 448.20 Cr |
| 2025-03-31 | 1,593.90 Cr | 2,199.60 Cr | -624.40 Cr | -1,442.60 Cr | 156.10 Cr | 1,459.30 Cr | 1,303.20 Cr | -766.20 Cr | 1,433.40 Cr |
| 2024-12-31 | 1,403.80 Cr | 662.00 Cr | -545.80 Cr | 59.00 Cr | 174.70 Cr | 1,303.20 Cr | 1,128.50 Cr | -881.90 Cr | -219.90 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-10-28 | October 28, 24 | 5:1 |
| 2006-08-28 | August 28, 06 | 2:1 |
| 2001-10-10 | October 10, 01 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council
Deepak Sapra
Gender: male
Year Born: 1975
CEO & Member of the Management Council
Erez Israeli
Gender: male
Year Born: 1968
Co-Chairman, MD & Member of Management Council
Gunupati Venkateswara Prasad
Gender: male
Year Born: 1960
Chairman of the Board & Member of the Management Council
Kallam Satish Reddy
Gender: male
Year Born: 1967
Global Head of Quality and Pharmacovigilance & Member of the Management Council
Krishna K. Venkatesh B.Pharma
Gender: male
Year Born: 1973
CFO & Member of the Management Council
Mannam Venkatanarasimham
Gender: male
Year Born: 1969
Head of Generics, Europe & Consumer Health and Member of Management Council
Patrick Aghanian
Gender: male
Year Born: 1965
Executive Vice President, Global Head of Global Manufacturing & Member of Management Council
Sanjay Sharma
Gender: male
Year Born: 1968
EVP, Head of Corporate Communications & Member of Management Council
Archana Bhaskar
Gender: female
Year Born: 1967
Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council
Motupalli Venkata Ramana
Gender: male
Year Born: 1969
FAQs about Dr. Reddy's Laboratories Limited
Who is the CEO of the company?
The CEO is Erez Israeli.
What is the current market price of the stock?
The current price is ₹1,294.40.
What is the 52-week price range?
The range is ₹1020-1379.7.
What is the market capitalization of the company?
The market capitalization is ₹107,769.27 crores.
What is the dividend yield?
The dividend yield is 0.62%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 19.05.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Dr. Reddy's Laboratories Limited (ISIN: INE089A01031) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹107,769.27 crores and an average daily volume of 1,560,919 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹8.